Review
Immunotherapy for renal cell carcinoma
Affiliations
- PMID: 1565900
Item in Clipboard
Review
Immunotherapy for renal cell carcinoma
Semin Urol.
1992 Feb.
Abstract
The prognosis for patients with metastatic renal cell carcinoma may be brightening. Immunotherapy may offer an effective alternative approach for this disease. Continuing advances in immunology and molecular biology will probably reinforce the early enthusiasm for this method. Although still investigational, cytokine monotherapy and combination therapy, adoptive immunotherapy, and gene therapy appear to be promising therapeutic modalities for selected patients with metastatic renal cell carcinoma.
Similar articles
-
Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.J Urol. 1999 Jul;162(1):46-50. doi: 10.1097/00005392-199907000-00012. J Urol. 1999. PMID: 10379737
-
Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.Cancer J Sci Am. 1998 Mar-Apr;4(2):86-93. Cancer J Sci Am. 1998. PMID: 9532410 Clinical Trial.
-
Management of metastatic renal cell carcinoma: current trends.Expert Rev Mol Diagn. 2009 Jan;9(1):75-83. doi: 10.1586/14737159.9.1.75. Expert Rev Mol Diagn. 2009. PMID: 19099350 Review.
-
New agents for the treatment of renal cell carcinoma.Expert Rev Anticancer Ther. 2001 Dec;1(4):546-54. doi: 10.1586/14737140.1.4.546. Expert Rev Anticancer Ther. 2001. PMID: 12113087 Review.
-
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.Cancer J Sci Am. 2000 Feb;6 Suppl 1:S88-92. Cancer J Sci Am. 2000. PMID: 10685666
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical